Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood...
Keep Reading →
September 28 - Hedge Funds, News
JPMorgan Chase & Co.'s (NYSE:JPM) asset management arm is set to deepen its relationship with one of the world's largest sovereign wealth funds through a planned $20 billion partnership...
Keep Reading →
September 28 - Hedge Funds, News
Johnson & Johnson's (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage...
Keep Reading →
September 28 - Hedge Funds, News
ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S.
Keep Reading →
September 28 - Hedge Funds, News
Guggenheim has assumed coverage of Nanobiotix S.A.
Keep Reading →
September 28 - Hedge Funds, News
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don't make for the most obvious comparison.
Keep Reading →
September 28 - Hedge Funds, News
Petróleo Brasileiro S.A.
Keep Reading →
September 28 - Hedge Funds, News
Alphabet Inc. (NASDAQ:GOOGL)'s Google has been hit with another major European regulatory penalty, this time over how it historically processed users' location data.
Keep Reading →
September 28 - Hedge Funds, News
Wells Fargo has put a number on the damage Boston Scientific Corporation's (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly...
Keep Reading →
September 28 - Hedge Funds, News
Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating.
Keep Reading →
September 28 - Hedge Funds, News
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways.
Keep Reading →
September 28 - Hedge Funds, News
Starbucks (NASDAQ:SBUX) is adding another piece to the infrastructure behind its turnaround, and this one sits thousands of miles from its headquarters.
Keep Reading →
September 28 - Hedge Funds, News
Spending on AI by hyperscalers is expanding so dramatically that electricity supply is becoming part of the investment story.
Keep Reading →
September 28 - Hedge Funds, News
Novo Nordisk (NYSE:NVO) finally has a CagriSema result it can put next to Eli Lilly's (NYSE:LLY) tirzepatide and come out ahead.
Keep Reading →
September 28 - Hedge Funds, News
Tesla (NASDAQ:TSLA) investors already have plenty to keep track of, from vehicle deliveries to the company's expansion into AI and autonomous driving.
Keep Reading →
September 28 - Hedge Funds, News
Healthcare has rarely been short of investment opportunities, but deciding where to look has become more complicated.
Keep Reading →
September 28 - Hedge Funds, News
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth.
Keep Reading →
September 28 - Hedge Funds, News
Warnings about artificial intelligence don't get much more extreme than this.
Keep Reading →
September 28 - Hedge Funds, News
Curtiss-Wright Corporation (NYSE:CW) isn't relying on one hot market to keep growing, with its products sitting across defense and commercial nuclear and marking two areas where...
Keep Reading →
September 28 - Hedge Funds, News
Enova International, Inc. (NYSE:ENVA) has abandoned a deal that was supposed to give the online lender something it has never had: its own bank.
Keep Reading →
September 28 - Hedge Funds, News
Prysmian is finding another way into the data-center buildout, and this time the story isn't about fiber.
Keep Reading →
September 27 - Hedge Funds, News
Apple Inc.
Keep Reading →
September 27 - Hedge Funds, News
Gilead Sciences, Inc.
Keep Reading →
September 27 - Hedge Funds, News
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth.
Keep Reading →
September 27 - Hedge Funds, News
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk.
Keep Reading →
September 27 - Hedge Funds, News
A decision easyJet (LON:EZJ) made in the weeks after Russia’s invasion of Ukraine has resurfaced more than four years later as a $72 million legal dispute.
Keep Reading →
September 27 - Hedge Funds, News
Pfizer Inc.
Keep Reading →
September 27 - Hedge Funds, News
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc.
Keep Reading →
September 27 - Hedge Funds, News
Warner Bros. Discovery, Inc. (NASDAQ:WBD) shareholders just got one of the biggest pieces of good news since Paramount Skydance (NASDAQ:PSKY) agreed to buy the company.
Keep Reading →
September 27 - Hedge Funds, News
Apple Inc. (NASDAQ:AAPL) is facing another regulatory headache in India, but this one isn't centered on the App Store or competition.
Keep Reading →
September 27 - Hedge Funds, News
SkyShowtime was supposed to give Comcast Corporation (NASDAQ:CMCSA) and Paramount Skydance Corporation (NASDAQ:PSKY) a more efficient route into European streaming.
Keep Reading →
September 27 - Hedge Funds, News
Apple Inc. (NASDAQ:AAPL) has one less AI battle to fight.
Keep Reading →
September 27 - Hedge Funds, News
Waymo is planning on entering Las Vegas, but it is not alone in the market there.
Keep Reading →
September 24 - Hedge Funds, News
Waymo has spent years proving that driverless taxis can operate commercially in U.S. cities, and is now taking the model to Tokyo to test whether it can work there.
Keep Reading →
September 24 - Hedge Funds, News
Grab Holdings Limited (NASDAQ:GRAB) could have spent years building out its consumer lending business across Southeast Asia. Instead, it is writing a $1.49 billion check.
Keep Reading →
September 24 - Hedge Funds, News
Toyota Motor Corporation (NYSE:TM) spent decades building its China business around two major partnerships: FAW in the north and GAC in the south.
Keep Reading →
September 24 - Hedge Funds, News
Goldman Sachs Group, Inc. (NYSE:GS) has another $11.7 billion to put to work in private equity.
Keep Reading →
September 24 - Hedge Funds, News
Johnson & Johnson (NYSE:JNJ) already has RYBREVANT approved across multiple EGFR-mutated advanced lung cancer settings.
Keep Reading →
September 24 - Hedge Funds, News
GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren't giving it enough credit.
Keep Reading →
September 24 - Hedge Funds, News
Contineum Therapeutics, Inc.
Keep Reading →
September 24 - Hedge Funds, News
Apple Inc.
Keep Reading →
September 24 - Hedge Funds, News
Alphabet Inc. (NASDAQ:GOOGL) has spent years fighting European regulators over how Google Search treats competing services.
Keep Reading →
September 24 - Hedge Funds, News
GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels.
Keep Reading →
September 24 - Hedge Funds, News
Amazon.com, Inc. (NASDAQ:AMZN) is no stranger to disputes over its massive workforce.
Keep Reading →
September 24 - Hedge Funds, News
Boeing (NYSE:BA) delivered fewer aircraft in August than it did a year earlier, but that headline misses the more interesting number for investors.
Keep Reading →
September 24 - Hedge Funds, News
GE Aerospace (NYSE:GE) has plenty of demand. Getting enough engines and parts out the door has been the harder part.
Keep Reading →
September 24 - Hedge Funds, News
Technical problems with Britain’s air traffic control system are becoming a recurring frustration for European airlines.
Keep Reading →
September 24 - Hedge Funds, News
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention.
Keep Reading →
September 24 - Hedge Funds, News
Roivant Sciences Ltd.
Keep Reading →
September 24 - Hedge Funds, News
